2-{[2-(4-nitrophenyl)ethyl]amino}ethanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{[2-(4-nitrophenyl)ethyl]amino}ethanol
• 英文别名: 2-(4-nitro-phenethylamino)-ethanol；2-(4-Nitro-phenaethylamino)-aethanol；2-[2-(4-Nitro-phenyl)-ethylamino]-ethanol；p-nitro-phenethylaminoethanol；2-[2-(4-nitrophenyl)ethylamino]ethanol
• 化学式: C₁₀H₁₄N₂O₃
• 分子量: 210.233
• InChiKey: BZOGBAPPHTZOBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  78.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-{[2-(4-nitrophenyl)ethyl]amino}ethanol 在 偶氮二甲酸二异丙酯 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 3-methyl-1-[2-(4-nitrophenyl)ethyl]piperazin-2-one
  参考文献：
  名称：

  [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
  [FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTÉRIEUR RÉNAL

  摘要：

  本发明提供了式（I）的化合物及其药学上可接受的盐，这些化合物是ROMK（Kir 1.1）通道的抑制剂。这些化合物作为利尿剂和钠利尿剂，并且是治疗和预防包括高血压和由过多盐和水潴留引起的疾病等医学状况的有价值的药用活性化合物。

  公开号：

  WO2013062892A1
• 作为产物：
  描述：

  1-氯-2-(4-硝基苯基)乙烷 、 C.I.酸性橙108 生成 2-{[2-(4-nitrophenyl)ethyl]amino}ethanol
  参考文献：
  名称：

  Barbiere, Bulletin de la Societe Chimique de France, 1944, vol. <5>11, p. 473

  摘要：

  DOI：

文献信息

• Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
  申请人：Ortuno Jean-Claude

  公开号：US20110034460A1

  公开（公告）日：2011-02-10

  Compounds of formula (I): wherein: m and n represent 1 or 2, A represents a pyrrolyl group, X represents a C(O), S(O) or SO 2 group, R 1 and R 2 represent an alkyl group or, together with the nitrogen atom carrying them, form a heterocyclic group, R 3 and R 4 , together with the atoms carrying them, form a heterocyclic group, R 5 represents a hydrogen atom or an alkyl group, R 6 represents a hydrogen atom or a halogen atom. Medicinal products containing the same which are useful in treating cancer.

  式（I）的化合物： 其中： m和n代表1或2， A代表吡咯基， X代表C（O）、S（O）或SO2基团， R1和R2代表烷基或与携带它们的氮原子一起形成杂环基团， R3和R4与携带它们的原子一起形成杂环基团， R5代表氢原子或烷基， R6代表氢原子或卤素原子。 含有这些化合物的药物，可用于治疗癌症。
• Hypolipidemic and antioxidant morpholine derivatives
  申请人：Elpen S.A.

  公开号：US06693192B1

  公开（公告）日：2004-02-17

  The present invention relates to the synthesis and the evaluation of the antioxidant, hypocholesterolemic and hypolipidemic activity of substituted morpholine derivatives of formula (I) in which R1=CH2CH3, R2=CH3, R3, R4=H, R5=C6H5 (compound 1) or R1=CH2CH2CH2ONO2, R2=CH3, R3, R4=H, R5=C6H5 (compound 2) or R1=H, R2—R3=(CH2)4, R4=H, R5=C6H5 (compound 3) or R1=CH2CH2CH3, R2—R3=(CH2)4, R4=H, R5=C6H5 (compound 4) or R1=CH2CH2CH2ONO2, R2—R3=(CH2)4, R4=H, R5=C6H5 (compound 5) or R1=H, R2=CH3, R3—R4=(CH2)4, R5=C6H5 (compound 6) or R1=CH2CH2CH3, R2=CH3, R3—R4=(CH2)4, R5=C6H5 (compound 7) or R1=CH2CH2CH2ONO2, R2=CH3, R3—R4=(CH2)4, R5=C6H5 (compound 8) or R1=CH2CH2CH2ONO2, R2=CH3, R3, R4=H, R5=C6H5 (compound 9) or R1=H, R2=p-NO2—C6H4—CH2CH2, R3, R4=H, R5=C6H5 (compound 10). The 2-hydroxy-morpholine derivatives 3, 6 and 10 are synthesised by the reaction of the appropriate aminoalcohol (22 mmol) and the 2-bromophenylacetophenone or the 2-bromoacetophenone (10 mmol) in ether and acetone for 15 hours at room temperature. Me 2-alkoxy derivatives 1, 4 and 7 are synthesised by the reaction of the respective 2-hydroxy derivative with the appropriate alcohol, in acid medium and reflux. Compounds 2, 5, 8 and 9 are synthesised by the reaction of the respective 2-hydroxy derivative with the 3-bromopropanol in acidic medium and reflux. The 2-(3-bromopropoxy) derivatives thin reacted with silver nitrate in acetonitrile and reflux. The compounds of formula (I) decrease significantly total cholesterol, triglyceride and LDL-cholesterol levels in plasma. The compounds of formula (I) possess potent antioxidant activity. The compounds of formula (I) with the above properties could be useful to the treatment of hypercholesterolemia, hyperlipidemia and atheromatosis.

  本发明涉及公式（I）的取代吗啡啶衍生物的合成和抗氧化剂、降胆固醇和降脂作用的评价，其中R1＝CH2CH3，R2＝CH3，R3、R4＝H，R5＝C6H5（化合物1）或R1＝CH2CH2CH2ONO2，R2＝CH3，R3、R4＝H，R5＝C6H5（化合物2）或R1＝H，R2-R3＝（CH2）4，R4＝H，R5＝C6H5（化合物3）或R1＝CH2CH2CH3，R2-R3＝（CH2）4，R4＝H，R5＝C6H5（化合物4）或R1＝CH2CH2CH2ONO2，R2-R3＝（CH2）4，R4＝H，R5＝C6H5（化合物5）或R1＝H，R2＝CH3，R3-R4＝（CH2）4，R5＝C6H5（化合物6）或R1＝CH2CH2CH3，R2＝CH3，R3-R4＝（CH2）4，R5＝C6H5（化合物7）或R1＝CH2CH2CH2ONO2，R2＝CH3，R3-R4＝（CH2）4，R5＝C6H5（化合物8）或R1＝CH2CH2CH2ONO2，R2＝CH3，R3、R4＝H，R5＝C6H5（化合物9）或R1＝H，R2＝p-NO2-C6H4-CH2CH2，R3、R4＝H，R5＝C6H5（化合物10）。通过在醚和丙酮中反应适当的氨基醇（22毫摩尔）和2-溴苯乙酮或2-溴乙酰苯（10毫摩尔）15小时，室温下合成了2-羟基吗啡啶衍生物3、6和10。通过在酸性介质和回流中将相应的2-羟基衍生物与适当的醇反应，合成了Me2-烷氧基衍生物1、4和7。化合物2、5、8和9是通过将相应的2-羟基衍生物与3-溴丙醇在酸性介质和回流中反应而合成的。将2-（3-溴丙氧基）衍生物与硝酸银在乙腈和回流中反应。公式（I）的化合物显著降低血浆总胆固醇、甘油三酯和LDL胆固醇水平。公式（I）的化合物具有强大的抗氧化活性。具有上述性质的公式（I）的化合物可能对治疗高胆固醇血症、高脂血症和动脉粥样硬化有用。
• [EN] HYPOLIPIDEMIC AND ANTIOXIDANT MORPHOLINE DERIVATIVES<br/>[FR] DERIVES DE MORPHOLINE HYPOLIPIDEMIQUES ET ANTIOXYDANTS
  申请人：ELPEN S A

  公开号：WO2000042030A1

  公开（公告）日：2000-07-20

  The present invention relates to the synthesis and the evaluation of the antioxidant, hypocholesterolemic and hypolipidemic activity of substituted morpholine derivatives of formula (I) in which R1=CH2CH3, R2=CH3, R3, R4=H, R5=C6H5 (compound 1) or R1=CH2CH2CH2ONO2, R2=CH3, R3, R4=H, R5=C6H5 (compound 2) or R1=H, R2-R3=(CH2)4, R4=H, R5=C6H5 (compound 3) or R1=CH2CH2CH3, R2-R3=(CH2)4, R4=H, R5=C6H5 (compound 4) or R1=CH2CH2CH2ONO2, R2-R3=(CH2)4, R4=H, R5=C6H5 (compound 5) or R1=H, R2=CH3, R3-R4=(CH2)4, R5=C6H5 (compound 6) or R1=CH2CH2CH3, R2=CH3, R3-R4=(CH2)4, R5=C6H5 (compound 7) or R1=CH2CH2CH2ONO2, R2=CH3, R3-R4=(CH2)4, R5=C6H5 (compound 8) or R1=CH2CH2CH2ONO2, R2=CH3, R3, R4=H, R5=H (compound 9) or R1=H, R2=p-NO2-C6H4-CH2CH2, R3, R4=H, R5=C6H5 (compound 10). The 2-hydroxy- morpholine derivatives 3, 6 and 10 are synthesised by the reaction of the appropriate aminoalcohol (22 mmol) and the 2-bromo-4-phenylacetophenone or the 2-bromoacetophenone (10 mmol) in ether and acetone for 15 hours at room temperature. The 2-alkoxy derivatives 1, 4 and 7 are synthesised by the reaction of the respective 2-hydroxy derivative with the appropriate alcohol, in acid medium and reflux. Compounds 2, 5, 8 and 9 are synthesised by the reaction of the respective 2-hydroxy derivative with the 3-bromopropanol in acidic medium and reflux. The 2-(3-bromopropoxy) derivatives then reacted with silver nitrate in acetonitrile and reflux. The compounds of formula (I) decrease significantly total cholesterol, triglyceride and LDL-cholesterol levels in plasma. The compounds of formula (I) possess potent antioxidant activity. The compounds of formula (I) with the above properties could be useful to the treatment of hypercholesterolemia, hyperlipidemia and atheromatosis.

  本发明涉及公式（I）的取代吗啡啶衍生物的合成和抗氧化剂、降胆固醇和降脂活性的评价，其中R1 = CH2CH3，R2 = CH3，R3，R4 = H，R5 = C6H5（化合物1）或R1 = CH2CH2CH2ONO2，R2 = CH3，R3，R4 = H，R5 = C6H5（化合物2）或R1 = H，R2-R3 =（CH2）4，R4 = H，R5 = C6H5（化合物3）或R1 = CH2CH2CH3，R2-R3 =（CH2）4，R4 = H，R5 = C6H5（化合物4）或R1 = CH2CH2CH2ONO2，R2-R3 =（CH2）4，R4 = H，R5 = C6H5（化合物5）或R1 = H，R2 = CH3，R3-R4 =（CH2）4，R5 = C6H5（化合物6）或R1 = CH2CH2CH3，R2 = CH3，R3-R4 =（CH2）4，R5 = C6H5（化合物7）或R1 = CH2CH2CH2ONO2，R2 = CH3，R3-R4 =（CH2）4，R5 = C6H5（化合物8）或R1 = CH2CH2CH2ONO2，R2 = CH3，R3，R4 = H，R5 = H（化合物9）或R1 = H，R2 = p-NO2-C6H4-CH2CH2，R3，R4 = H，R5 = C6H5（化合物10）。通过在乙醚和丙酮中反应适当的氨基醇（22 mmol）和2-溴-4-苯乙酮或2-溴苯乙酮（10 mmol），在室温下反应15小时，合成了2-羟基吗啡啶衍生物3、6和10。通过在酸性介质和回流条件下，将相应的2-羟基衍生物与适当的醇反应，合成了2-烷氧基衍生物1、4和7。化合物2、5、8和9通过将相应的2-羟基衍生物与3-溴丙醇在酸性介质和回流条件下反应而合成。然后将2-(3-溴丙氧基)衍生物与硝酸银在乙腈和回流条件下反应。公式（I）的化合物显著降低血浆总胆固醇、甘油三酯和LDL-胆固醇水平。公式（I）的化合物具有强大的抗氧化活性。具有上述性质的公式（I）的化合物可能对治疗高胆固醇血症、高脂血症和动脉粥样硬化有用。
• Novel urea derivatives
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：US20020198376A1

  公开（公告）日：2002-12-26

  Objects of the present invention are to create compounds having urea structure as basic structure and having a sulfur atom and an amide bond in side chains and to find pharmacological effects thereof, particularly TNF-&agr; production inhibitory effects. The present invention provides compounds represented by the following formula [I] wherein R 1 is H, alkyl, aromatic, R A —CO—, R C —S— or the formula [II]; R 2 , R 3 and R 4 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R 5 and R 6 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R 5 and R 6 can together form a nonaromatic heterocyclic ring; R7 is H, alkyl, cycloalkyl, hydroxy, mercapto, phenyl, R B —O—, R C —S—, R D —COS—, R E —OCO—, R F —N(R G )— or —CONHOH; and A 1 and A 2 are alkylene. 1

  本发明的目的是创建具有尿素结构作为基本结构并在侧链中具有硫原子和酰胺键的化合物，并发现其药理作用，特别是TNF-α生产抑制作用。本发明提供由以下式子（I）表示的化合物，其中R1为H、烷基、芳香基、RA—CO—、RC—S—或式子（II）；R2、R3和R4为H、烷基、烯基、环烷基、环烯基或芳香基；R5和R6为H、烷基、烯基、环烷基、环烯基或芳香基；R5和R6可以一起形成非芳香杂环；R7为H、烷基、环烷基、羟基、巯基、苯基、RB—O—、RC—S—、RD—COS—、RE—OCO—、RF—N(RG)—或—CONHOH；A1和A2为烷基。
• Inhibitors of the Renal Outer Medullary Potassium Channel
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140296225A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.

  本发明提供了I式化合物及其药物可接受的盐，它们是ROMK（Kir1.1）通道的抑制剂。这些化合物作为利尿剂和排钠剂，并且是治疗和预防包括高血压和由过多盐和水潴留引起的医疗状况的有价值的药物活性化合物。